Targeting NUDT21 siRNA drugs

Phase 1Small molecule

EEye & ENT Hospital of Fudan University

Targeting NUDT21 siRNA drugs is one of 18 small molecule programs targeting Retinoblastoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

RetinoblastomaRecruiting

RetinoblastomaPhase 1

Recruiting

Competition

Competitive Landscape

21 competitors in Retinoblastoma

#DrugCompanyPhaseTrials

Oncovin

Eli Lilly

Phase 3

6 2

Paraplatin

AAvyxa

Phase 3

14 3

Vepesid

AAvyxa

Phase 3

9 4

Alkeran

AApotex Inc.

Phase 3

8 5

Neupogen

EEastern Cooperative Oncology Group

Phase 3

6 6

Hycamtin

MMeitheal

Phase 3

5 7

Cytoxan

BBaxter Healthcare Corporation

Phase 3

3 8

Oncovin

Eli Lilly

Phase 2

4 9

Adriamycin

Pfizer

Phase 2

1 10

Neoral

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Retinoblastoma1 trial

Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma

Recruiting·EEye & ENT Hospital of Fudan University·Phase 1·NCT06424301·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Targeting NUDT21 siRNA drugs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Targeting NUDT21 siRNA drugs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Targeting NUDT21 siRNA drugs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eye & ENT Hospital of Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: EEye & ENT Hospital of Fudan University

Targeting NUDT21 siRNA drugs

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Retinoblastoma1 trial

References

Drug Info

Quick Facts

Related News